X4 Pharma Extends Cash Runway to 2029, Advances Phase 3 Trial with FDA Update Expected by Q3 End
XFOR has more than doubled off its 52-week low of $1.35.
Summary
X4 Pharmaceuticals reported Q2 2026 results with a cash position of $208M, extending its runway into 2029—a significant improvement from the 12-month runway noted in the last 10-Q. Revenue reached $8.8M for the quarter, driven by XOLREMDI U.S. sales and Norgine license revenue. The company has overhauled its Phase 3 4WARD trial operations, engaging a top CRO and activating over 110 sites, with an FDA meeting and enrollment completion update expected by the end of Q3. EU marketing authorization for XOLREMDI was transferred to partner Norgine, unlocking up to €221M in milestones plus double-digit royalties. The extended cash runway and operational progress reduce near-term financing risk and position the company for key catalysts.
At the time of this announcement, XFOR was trading at $4.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $393.3M. The 52-week trading range was $1.35 to $4.83. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.